Sphere Fluidics is a Cambridge(UK)-based Life Sciences R&D company that specializes in biopharmaceutical discovery and development, cell therapy engineering, bioproduction and synthetic biology, analysis and isolation.

[2][4][5] November 2021: Sphere Fluidics raised $40M led by Paris-based Sofinnova Partners and San Francisco-based Redmile Group.

[6][4][3][5] Cyto-Mine is a patented single cell analysis and characterisation system by Sphere Fluidics.

This technology is said to aid the development of biotherapeutics for treatment of cancer and inflammatory diseases and vaccine generation.

The addition of S-LAB to the Cyto-Mine provides researchers with a further streamlined solution for single cell analysis in biopharmaceutical workflows.